<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908972</url>
  </required_header>
  <id_info>
    <org_study_id>12172-MM-231</org_study_id>
    <nct_id>NCT01908972</nct_id>
  </id_info>
  <brief_title>The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma</brief_title>
  <official_title>The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficiency of Propranolol as an
      initial treatment for pediatric hemangioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Randomized (A group : propranolol, B group : prednisolone)

        -  A group : 3 days admission and medication for 16 weeks

        -  B group : medication for 16 weeks without admission

        -  Hemangioma volume comparison by using MRI

        -  other measurement and drug adverse reaction monitoring
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO</measure>
    <time_frame>After 16weeks</time_frame>
    <description>The primary efficacy variable was the clinical response at 16 weeks, classified as follows: when the volume did not increase or decreased by less than 25% after treatment began, we defined it as stop of progression; when the volume decreased by 25% or more compared with the original size, we defined it as regression. Both stop of progression and regressionwere defined as reaction. If the volume at the primary efficacy evaluation point was greater than the size measured when treatment started,we called it an increase. Increase was defined as a nonreaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in Hemangioma Volume From Baseline</measure>
    <time_frame>After 16 weeks</time_frame>
    <description>Percent Reduction in Hemangioma Volume from Baseline (measured by MRI or Sono (from basline to 16 weeks))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Which, the Heart Rate Fell to &lt;70% of Acceptable Age Related Minimum Post-dose With Child Awake, Anytime During the 16 Weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>Number of Participants in which, the Heart rate fell to &lt;70% of acceptable age related minimum post-dose with child awake, anytime during the 16 weeks Count of patients whose Heart rate fall to &lt;70% of acceptable age related minimum post-dose with child awake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Color as Compared to Baseline</measure>
    <time_frame>After 16 weeks</time_frame>
    <description>Participants were observed for any change in color. The possible change in colors included change to Red/Purple/Blue/Gray/Apricot. Reported are the number of participants who experienced a change in color by the type of color</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Size Reduction of Ulceration</measure>
    <time_frame>After 16 weeks</time_frame>
    <description>size was measure the horizontal and vertical size (2-dimension) of ulceration (from baseline to 16 weeks after medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Reepithelialzation in 16weeks</measure>
    <time_frame>After 16 weeks</time_frame>
    <description>Number of participants with Reepithelialzation in 16weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stop of Proliferation</measure>
    <time_frame>After 16 weeks</time_frame>
    <description>Number of participants whose hemangioma stop proliferating in 16weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Regression</measure>
    <time_frame>Within 16 weeks</time_frame>
    <description>Number of participants whose hemangioma showed regression in 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Compliance Within 16 Weeks</measure>
    <time_frame>After 16 weeks</time_frame>
    <description>We checked Number of participants with Drug compliance within 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Which, the Systolic Blood Pressure Fall of &gt;25% of Baseline Postdose With Child Awake, Anytime During the 16 Weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>Number of Participants in Which, the Systolic blood pressure fall of &gt;25% of baseline postdose with child awake, Anytime During the 16 Weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Which, Glucose Levels Fall (to &lt;50mg/dl), Anytime During the 16 Weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>Number of Participants in Which, Glucose levels fall (to &lt;50mg/dl), Anytime During the 16 Weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Which, Facial Edema Occurs, Anytime During the 16 Weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>Number of Participants in Which, facial edema occurs, Anytime During the 16 Weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Growth Retardation Within 16 Weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>Number of Participants with Growth Retardation within 16 weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gastroesophageal Reflux Within 16 Weeks</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>Number of Participants With Gastroesophageal reflux within 16 weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reaction</measure>
    <time_frame>up to 16weeks</time_frame>
    <description>All symptoms associated adverse drug reaction will be checked</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>2mg/kg/day for 16weeks</description>
    <arm_group_label>Prednisolone</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>2mg/kg/day for 16weeks</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>beta-blocker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemangioma patient ( 0 ~ 9 months old)

          -  No treatment before

          -  10 ~ 20 % volume increase in 2 ~ 4 weeks

          -  Hemangioma that caused organ function

          -  Hemangioma that will cause aesthetic problem

        Exclusion Criteria:

          -  Cardiovascular disease (impossible to use propranolol)

          -  Drug adverse reaction or allergy history (propranolol, steroid)

          -  Bradycardia, Atrioventricular block, atrial block

          -  Cardiogenic Shock

          -  Right heart failure (pulmonary hypertension)

          -  Congestive heart failure

          -  Hypotension

          -  Peripheral nerve disease (moderate)

          -  Angina

          -  Hormone deficiency patient

          -  Pulmonary disease (asthma)

          -  diabetic ketoacidosis

          -  laser treatment history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>9 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Duk Park, MD, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Hyun Choi, MD, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seould National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <results_first_submitted>October 29, 2017</results_first_submitted>
  <results_first_submitted_qc>January 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2018</results_first_posted>
  <last_update_submitted>November 29, 2018</last_update_submitted>
  <last_update_submitted_qc>November 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemangioma</keyword>
  <keyword>Propranolol</keyword>
  <keyword>prednisolone</keyword>
  <keyword>steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prednisolone</title>
          <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
        </group>
        <group group_id="P2">
          <title>Propranolol</title>
          <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prednisolone</title>
          <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
        </group>
        <group group_id="B2">
          <title>Propranolol</title>
          <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" lower_limit="0.8" upper_limit="8.0"/>
                    <measurement group_id="B2" value="3.6" lower_limit="0.3" upper_limit="8.2"/>
                    <measurement group_id="B3" value="3.3" lower_limit="0.3" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemangioma volume by MRI</title>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9,349" spread="16,015"/>
                    <measurement group_id="B2" value="14,125" spread="18,246"/>
                    <measurement group_id="B3" value="11,737" spread="3348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO</title>
        <description>The primary efficacy variable was the clinical response at 16 weeks, classified as follows: when the volume did not increase or decreased by less than 25% after treatment began, we defined it as stop of progression; when the volume decreased by 25% or more compared with the original size, we defined it as regression. Both stop of progression and regressionwere defined as reaction. If the volume at the primary efficacy evaluation point was greater than the size measured when treatment started,we called it an increase. Increase was defined as a nonreaction.</description>
        <time_frame>After 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO</title>
          <description>The primary efficacy variable was the clinical response at 16 weeks, classified as follows: when the volume did not increase or decreased by less than 25% after treatment began, we defined it as stop of progression; when the volume decreased by 25% or more compared with the original size, we defined it as regression. Both stop of progression and regressionwere defined as reaction. If the volume at the primary efficacy evaluation point was greater than the size measured when treatment started,we called it an increase. Increase was defined as a nonreaction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in Hemangioma Volume From Baseline</title>
        <description>Percent Reduction in Hemangioma Volume from Baseline (measured by MRI or Sono (from basline to 16 weeks))</description>
        <time_frame>After 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in Hemangioma Volume From Baseline</title>
          <description>Percent Reduction in Hemangioma Volume from Baseline (measured by MRI or Sono (from basline to 16 weeks))</description>
          <units>% from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.52" spread="26.24"/>
                    <measurement group_id="O2" value="55.87" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Which, the Heart Rate Fell to &lt;70% of Acceptable Age Related Minimum Post-dose With Child Awake, Anytime During the 16 Weeks</title>
        <description>Number of Participants in which, the Heart rate fell to &lt;70% of acceptable age related minimum post-dose with child awake, anytime during the 16 weeks Count of patients whose Heart rate fall to &lt;70% of acceptable age related minimum post-dose with child awake</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which, the Heart Rate Fell to &lt;70% of Acceptable Age Related Minimum Post-dose With Child Awake, Anytime During the 16 Weeks</title>
          <description>Number of Participants in which, the Heart rate fell to &lt;70% of acceptable age related minimum post-dose with child awake, anytime during the 16 weeks Count of patients whose Heart rate fall to &lt;70% of acceptable age related minimum post-dose with child awake</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Color as Compared to Baseline</title>
        <description>Participants were observed for any change in color. The possible change in colors included change to Red/Purple/Blue/Gray/Apricot. Reported are the number of participants who experienced a change in color by the type of color</description>
        <time_frame>After 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Color as Compared to Baseline</title>
          <description>Participants were observed for any change in color. The possible change in colors included change to Red/Purple/Blue/Gray/Apricot. Reported are the number of participants who experienced a change in color by the type of color</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Size Reduction of Ulceration</title>
        <description>size was measure the horizontal and vertical size (2-dimension) of ulceration (from baseline to 16 weeks after medication)</description>
        <time_frame>After 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Size Reduction of Ulceration</title>
          <description>size was measure the horizontal and vertical size (2-dimension) of ulceration (from baseline to 16 weeks after medication)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Reepithelialzation in 16weeks</title>
        <description>Number of participants with Reepithelialzation in 16weeks..</description>
        <time_frame>After 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reepithelialzation in 16weeks</title>
          <description>Number of participants with Reepithelialzation in 16weeks..</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stop of Proliferation</title>
        <description>Number of participants whose hemangioma stop proliferating in 16weeks</description>
        <time_frame>After 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stop of Proliferation</title>
          <description>Number of participants whose hemangioma stop proliferating in 16weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Regression</title>
        <description>Number of participants whose hemangioma showed regression in 16 weeks.</description>
        <time_frame>Within 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Regression</title>
          <description>Number of participants whose hemangioma showed regression in 16 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug Compliance Within 16 Weeks</title>
        <description>We checked Number of participants with Drug compliance within 16 weeks</description>
        <time_frame>After 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Compliance Within 16 Weeks</title>
          <description>We checked Number of participants with Drug compliance within 16 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Which, the Systolic Blood Pressure Fall of &gt;25% of Baseline Postdose With Child Awake, Anytime During the 16 Weeks</title>
        <description>Number of Participants in Which, the Systolic blood pressure fall of &gt;25% of baseline postdose with child awake, Anytime During the 16 Weeks..</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which, the Systolic Blood Pressure Fall of &gt;25% of Baseline Postdose With Child Awake, Anytime During the 16 Weeks</title>
          <description>Number of Participants in Which, the Systolic blood pressure fall of &gt;25% of baseline postdose with child awake, Anytime During the 16 Weeks..</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Which, Glucose Levels Fall (to &lt;50mg/dl), Anytime During the 16 Weeks</title>
        <description>Number of Participants in Which, Glucose levels fall (to &lt;50mg/dl), Anytime During the 16 Weeks..</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which, Glucose Levels Fall (to &lt;50mg/dl), Anytime During the 16 Weeks</title>
          <description>Number of Participants in Which, Glucose levels fall (to &lt;50mg/dl), Anytime During the 16 Weeks..</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Which, Facial Edema Occurs, Anytime During the 16 Weeks</title>
        <description>Number of Participants in Which, facial edema occurs, Anytime During the 16 Weeks..</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which, Facial Edema Occurs, Anytime During the 16 Weeks</title>
          <description>Number of Participants in Which, facial edema occurs, Anytime During the 16 Weeks..</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Growth Retardation Within 16 Weeks</title>
        <description>Number of Participants with Growth Retardation within 16 weeks..</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Growth Retardation Within 16 Weeks</title>
          <description>Number of Participants with Growth Retardation within 16 weeks..</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Gastroesophageal Reflux Within 16 Weeks</title>
        <description>Number of Participants With Gastroesophageal reflux within 16 weeks..</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastroesophageal Reflux Within 16 Weeks</title>
          <description>Number of Participants With Gastroesophageal reflux within 16 weeks..</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reaction</title>
        <description>All symptoms associated adverse drug reaction will be checked</description>
        <time_frame>up to 16weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
            <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reaction</title>
          <description>All symptoms associated adverse drug reaction will be checked</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prednisolone</title>
          <description>Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
Prednisolone: 2mg/kg/day for 16weeks</description>
        </group>
        <group group_id="E2">
          <title>Propranolol</title>
          <description>Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
Propranolol: 2mg/kg/day for 16weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Blood pressure &lt;25%</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although the sample size in the present study was predetermined to show noninferiority, it is difficult to provide strong evidence of safety outcomes.
The present study was not a double-blind trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Tae Hyun Choi</name_or_title>
      <organization>Seoul National University College of Medicine</organization>
      <phone>82-10-5595-5829</phone>
      <email>psthchoi@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

